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Abstract
Objective—To investigate whether adiposity influences endothelial progenitor cell (EPC) 
number and colony-forming capacity.
Design—Cross-sectional study of normal weight, overweight and obese adult humans.
Subjects—Sixty-seven sedentary adults (age 45–65y): 25 normal weight (BMI ≤ 25 kg/m2; 12 
males/13 females); 18 overweight (BMI = 25–29.9 kg/m2; 12 males/6 females); and 24 obese 
(BMI ≥ 30 kg/m2; 18 males/6 females). All subjects were non-smokers and free of overt 
cardiometabolic disease.
Measurements—Peripheral blood samples were collected and circulating EPC number was 
assessed by flow cytometry. Putative EPCs were defined as CD45−/CD34+/VEGFR-2+/CD133+ or 
CD45−/CD34+ cells. EPC colony-forming capacity was measured in vitro using a colony-forming 
unit assay.
Results—Number of circulating putative EPCs (either CD45−/CD34+/VEGFR-2+/CD133+ or 
CD45−/CD34+ cells) was lower (P<0.05) in obese (0.0007±0.0001%; 0.050±0.006%) compared 
with overweight (0.0016±0.0004%; 0.089±0.019%) and normal weight (0.0015±0.0003%; 
0.082±0.008%) adults. There were no differences in EPC number between the overweight and 
normal weight groups. EPC colony-formation was significantly less in the obese (6±1) and 
overweight (4±1) compared with normal weight (9±2) adults.
Conclusion—These results indicate that: 1) the number of circulating EPCs is lower in obese 
compared with overweight and normal weight adults; and 2) EPC colony-forming capacity is 
blunted in overweight and obese adults compared with normal weight adults. Impairments in EPC 
number and function may contribute to adiposity-related cardiovascular risk.
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INTRODUCTION
Overweight and obesity are associated with increased rates of cardiovascular morbidity 
and mortality (1;2)
Endothelial damage and dysfunction is considered to be a major underlying mechanism for 
the heightened cardiovascular burden with increased adiposity. For example, alterations in 
endothelial function associated with overweight and obesity that precede and predispose to 
atherosclerosis and thrombosis include diminished endothelial vasodilator and fibrinolytic 
function (3;4). Although much attention has focused on factors that contribute to adiposity-
related endothelial damage, such as inflammation and oxidative stress, recent studies 
indicate that endogenous endothelial repair and neovascularization processes also play an 
important role in vascular health and function.
It is now recognized that endothelial repair/regeneration is not only dependent upon the 
migration and proliferation of surrounding mature endothelial cells resident in the vascular 
wall, but also on the availability of circulating endothelial progenitor cells (EPCs) (5). 
Characterized in 1997 by Asahara and colleagues (6), EPCs possess the ability to proliferate, 
migrate, differentiate into mature endothelial cells and incorporate into preexisting and 
newly-forming blood vessels (6–9). Circulating EPCs have also generated interest as a novel 
biomarker of endothelial function and a prognostic indicator of cardiovascular morbidity and 
mortality. Two recent clinical studies reported that reduced levels of circulating EPCs 
independently predict atherosclerotic disease progression and death from cardiovascular 
causes in patients with established coronary artery disease (CAD) (10;11). Moreover, after 
adjusting for disease activity and risk factors, low numbers of circulating EPCs were 
associated with a four-fold increased risk of a future cardiovascular event (10). In addition, 
Kunz et al. (12) reported a strong inverse relation between EPC colony-forming capacity 
and CAD severity in individuals undergoing diagnostic cardiac catheterization, independent 
of traditional risk factors. Interestingly, the investigators noted that for every 10 EPC 
colony-forming unit increase, the likelihood of multivessel CAD declined by 20%. 
Numerical and functional deficits in circulating EPCs have also been linked to restenosis 
rates and impaired neovascularization after ischemic events (5;13).
Although reduced number and impaired function of EPCs have been linked to a number of 
pathologies associated with overweight/obesity, such as hypertension, hypercholesterolemia, 
diabetes and CAD (14–16), the influence of increased adiposity per se on circulating EPCs 
remains unclear. Accordingly, we tested the hypotheses that: 1) the number of circulating 
EPCs is lower in otherwise healthy overweight and obese compared with normal weight 
adults; and 2) EPC colony-forming capacity is also diminished in overweight and obese 
adults.
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METHODS
Subjects
Sixty seven sedentary adults aged 45–65 years participated in the study: 25 normal weight 
(BMI >18.5 kg/m2 and <25 kg/m2; 12 male/13 female); 18 overweight (BMI ≥ 25 kg/m2 
and ≤ 30 kg/m2; 12 M/6 F); and 24 obese (BMI ≥ 30 kg/m2; 18 M/6 F). All subjects were 
normotensive (arterial blood pressure ≤ 140/90 mmHg), non-smokers, non-medicated 
(including vitamins), and free of overt cardiovascular, metabolic, renal and hematologic 
disease, as assessed by medical history, resting and exercise electrocardiograms, and fasting 
blood chemistries. Subjects were excluded from the study if they exhibited plasma glucose 
>7.0 mmol/L; total cholesterol ≥ 6.0 mmol/L, LDL-cholesterol ≥ 4.5 mmol/L, triglycerides 
≥ 2.5 mmol/L. All subjects were sedentary and had not performed regular physical exercise 
for at least 1 year before the beginning of the study. Female subjects were at least 1 year 
postmenopausal and had never taken or had discontinued use of hormone replacement 
therapy at least 1 year before the start of the study. Prior to participation, all of the subjects 
had the research study and its potential risks and benefits explained fully before providing 
written informed consent according to the guidelines of the University of Colorado at 
Boulder. We certify that all applicable institutional and governmental regulations concerning 
the ethical use of human volunteers were followed during this research.
Body Composition
Body mass was measured to the nearest 0.1 kg using a medical beam balance. Percent body 
fat was determined by dual energy X-ray absorptiometry (Lunar Corp., Madison, WI, USA). 
Body mass index (BMI) was calculated as weight (kilograms) divided by height (meters) 
squared. Minimal waist circumference was measured according to published guidelines (17).
Maximal Oxygen Consumption (V̇ O2 max)
To assess aerobic fitness, subjects performed incremental treadmill exercise using a 
modified Balke protocol. Maximal oxygen consumption (V̇O2 max) was measured using on-
line computer-assisted open circuit spirometry, as reported previously (18).
Metabolic Measurements
Fasting plasma lipid, lipoprotein, glucose, and insulin concentrations were determined using 
standard techniques, as reported previously (3). Insulin resistance (HOMA-IR) was 
calculated according to the HOMA calculation: fasting insulin (μU/mL) × fasting glucose 
(mmol/L)/22.5 (19).
EPC Isolation and Characterization
Circulating mononuclear cells were isolated from peripheral blood sample by Ficoll density-
gradient centrifugation (Histopaque 1077, Sigma Aldrich, St. Louis, MO, USA), washed and 
resuspended in growth medium (Medium 199, Gibco, Grand Island, NY, USA) 
supplemented with 20% fetal calf serum (Gibco), penicillin (100 U/mL, Gibco), and 
streptomycin (100 mg/mL, Gibco). Endothelial phenotype of these cells was confirmed by 
immunofluorescent staining for the uptake of DiI-ac-LDL (Biomedical Technologies Inc., 
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Stoughton, MA, USA) and expression of von Willebrand factor (Dako, Glostrup, Denmark), 
VE-cadherin, CD31, and VEGFR-2 (Invitrogen, Carlsbad, CA, USA).
EPC Number
Circulating putative EPC number was determined by fluorescence-activated cell sorting 
(FACS) analysis following guidelines recommended by the International Society for 
Hematotherapy and Graft Engineering (20). Briefly, 2 × 106 cells were incubated at 4 °C for 
30 minutes with monoclonal antibodies for PC7-conjugated CD45 (Beckman Coulter, 
Fullerton, CA, USA), FITC-conjugated CD34 (Beckman Coulter), PE-conjugated VEGFR-2 
(R&D Systems, Minneapolis, MN, USA) and APC-conjugated CD133 (Miltenyi Biotech, 
Auburn, CA, USA). Non-viable cells were excluded with propidium iodide (Sigma-Aldrich, 
St. Louis, MO, USA) and appropriate compensation controls were analyzed. Cells were 
gated for low expression of CD45, then CD34+ cells were analyzed for events double-
positive for VEGFR-2 and CD133 and presented as a percent of total viable mononuclear 
cells. All samples were analyzed using a FC500 flow cytometer (Beckman Coulter) and the 
data analyzed by CXP software.
EPC Colony-Forming Assay
EPC colony-forming capacity was determined as described previously by our laboratory and 
others (16;21). Briefly, freshly isolated mononuclear cells were plated on 6-well plates 
coated with human fibronectin (BD Biosciences, San Jose, CA, USA) for 48 hours at 37 °C. 
Thereafter, 5 × 105 non-adherent cells from each subject were seeded onto 24-well 
fibronectin-coated plates (BD Biosciences). Growth medium was changed every 3 days, and 
the colony-forming units (CFUs) were counted in 4 random wells on day 7 by two 
independent investigators blinded to sample identification. Only CFUs consisting of 
multiple thin, flat cells emanating from a central cluster of rounded cells were counted.
Statistical Analysis
Group differences were determined by analysis of variance. Where indicated by a significant 
F value, Duncan’s post hoc test was performed to compare specific group means. 
Importantly, no main effects of gender, nor interactions of gender with BMI group, were 
found in any of the key outcome variables. Therefore, the data were combined and presented 
together. Relations between variables of interest were assessed by Pearson’s correlation 
coefficient and linear regression analysis. All data are expressed as means ± SE. Statistical 
significance was set a priori at P < 0.05.
RESULTS
Selected subject characteristics are presented in Table 1. All subjects were normotensive, 
normolipidemic, and normoglycemic. By design, body mass and body composition values 
were significantly higher (P<0.05) in the overweight and obese groups compared with the 
normal weight group. Although within clinically normal ranges, obese subjects 
demonstrated higher (P<0.05) resting systolic and diastolic blood pressure, and lower 
(P<0.05) HDL-cholesterol, than the normal weight controls. Obese subjects also had 
significantly higher plasma insulin concentrations and HOMA insulin resistance values 
MacEneaney et al. Page 4
Int J Obes (Lond). Author manuscript; available in PMC 2009 August 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
compared with both the normal weight and overweight subjects. There were no differences 
amongst the groups in plasma concentrations of total cholesterol, LDL-cholesterol, 
triglycerides, and glucose.
The number of CD45−/CD34+/VEGFR-2+/CD133+ cells was ~50% lower (P<0.05) in the 
obese (0.0007 ± 0.0001 %) compared with the overweight (0.0016 ± 0.0004 %) and normal 
weight groups (0.0015 ± 0.0003 %) (Figure 1). Similarly, the number of CD45−/CD34+ cells 
was lower (P<0.05) in the obese (0.050±0.006%) compared with overweight 
(0.089±0.019%) and normal weight subjects (0.082±0.008%). There were no significant 
differences in either CD45−/CD34+/VEGFR-2+/CD133+ or CD45−/CD34+ cells between the 
overweight and normal-weight subjects. The capacity of EPCs to form colonies was lower 
(~40%; P<0.05) in both the overweight (4 ± 1) and obese (6 ± 1) groups versus the normal 
weight controls (9 ± 2) (Figure 2). There was no significant difference in EPC CFU number 
between the overweight and obese subjects.
In the overall study population, there were significant inverse relations between BMI and the 
number of CD45−/CD34+/VEGFR-2+/CD133+ cells (r = −0.25), CD45−/CD34+ cells (r = 
−0.26) and EPC colony forming units (r = −0.24). Percent body fat was also negatively 
associated with the number of CD45−/CD34+ cells (r = −0.25, P<0.05). No other significant 
correlations were observed between either EPC number or colony-forming capacity and any 
other anthropometric, metabolic or hemodynamic variable.
DISCUSSION
The new findings of the present study are that: 1) the number of circulating EPCs is lower in 
obese compared with overweight and normal weight adults; and 2) EPC colony-forming 
capacity is blunted in overweight and obese adults compared with normal weight adults. To 
our knowledge, this is the first study to demonstrate adiposity-related impairments in EPC 
number and function in overweight and obese adults free of other cardiometabolic 
abnormalities.
Many of the cardiovascular complications associated with obesity are due, at least in part, to 
endothelial damage and/or dysfunction (22;23). Circulating EPCs are considered to be an 
important hemostatic mechanism for counteracting endothelial injury and the accelerated 
development of atherosclerosis associated with many cardiovascular risk factors, including 
obesity (24). For example, circulating EPC number is inversely related to the extent of 
carotid stenosis and lower extremity atherosclerosis in obese diabetic patients (25). 
Moreover, in patients with CAD, higher numbers of circulating EPCs have been linked to 
greater myocardial perfusion and vascularization (26;27) as well as overall better prognosis 
(10). To date, previous investigations evaluating the influence of adiposity on progenitor cell 
number have been hampered by design limitations involving the presence of multiple 
cardiovascular risk factors, overt disease and/or medication use, making it difficult to 
discern the impact of obesity per se on EPC number (28;29). In the present study, we 
demonstrate that the number of circulating putative EPCs, presented as CD45−/CD34+/
VEGFR-2+/CD133+ cells as well as CD45−/CD34+ cells, is close to 50% lower in obese 
compared with overweight and normal weight adults. The absence of other established 
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cardiometabolic risk factors in our study population suggests a primary negative influence of 
obesity on EPC number. From a clinical perspective, it is plausible that reduced EPC 
bioavailability may contribute to the increased incidence of endothelium-related vascular 
complications and reduced neovascularization with obesity (30–32). Interestingly, EPC 
number was not lower in the overweight compared with normal weight group. The number 
of CD45−/CD34+/VEGFR-2+/CD133+ and CD45−/CD34+ cells in the overweight adults was 
almost identical to that of the normal weight controls and, in turn, significantly higher than 
the obese adults. This finding was unexpected considering we have previously reported no 
differences in the degree of endothelial vasodilator and fibrinolytic dysfunction between 
overweight and obese adults similar to those studied herein (3;33). Nevertheless, greater 
number of EPCs in overweight adults may play a role in their lower risk of recurrent 
coronary events following acute myocardial infarction compared with obese adults of 
similar age (34).
The mechanisms responsible for the obesity-related reduction in circulating putative EPC 
number are not clear. Although we employed strict inclusion criteria in the present study, the 
obese adults did demonstrate higher, albeit in clinically normal ranges, levels of blood 
pressure, plasma insulin and insulin resistance. Thus, it is possible that the cumulative 
effects of these factors, along with other secondary consequences of excess body fatness, 
such as oxidative stress and inflammation, creates an environment resulting in higher 
consumption and/or exhaustion of EPC production. For example, the inflammatory cytokine 
C-reactive protein, although not measured in the present study, is often higher in obese 
compared with overweight and normal weight adults (35). C-reactive protein has been 
shown to promote apoptosis in EPCs in vitro (36), which could negatively impact circulating 
EPC number. Differences in body fat distribution between the overweight and obese 
subjects may also have contributed to our findings. Future studies are needed to determine 
whether differences in visceral and subcutaneous body fat depots influence EPC number.
There are conflicting reports in the literature regarding the appropriate defining criteria for 
the quantification of EPCs. Circulating EPCs are thought to be primarily derived from 
hematopoietic stem cells, however, non-hematopoietic mesenchymal stem cells and other 
monocytic cells from peripheral blood have also been shown to cross-differentiate into 
functionally active endothelial progenitors, or assume an endothelial-like phenotype (37;38). 
It has been suggested that the best strategy for enumeration is to isolate cells positive for 
both a hematopoietic stem cell surface membrane protein, such as CD34, and a marker of 
endothelial lineage, such as VEGFR-2, by flow cytometry (39). However, the antigen CD34 
can also be weakly expressed in mature endothelial cells (40), that are also present in the 
circulation (41). As a result, it has been proposed that the immature hematopoietic stem cell 
marker CD133 also be used for enumeration (42;43). Peichev et al. demonstrated that 
circulating CD34+/VEGFR-2+/CD133+ cells differentiate into endothelial cell clusters in 
vitro and may also contribute to neoangiogenesis (40). In contrast, Case et al. (44) recently 
reported that CD34+/VEGFR-2+/CD133+ cells do not differentiate into endothelial cells, 
raising some doubt regarding their EPC designation. However, because the cells were 
cultured in isolation, devoid of interaction with other cell lines (a situation never 
encountered in vivo), it is possible that the culture conditions influenced the results. Of note, 
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the same study also reported that CD34+ cells with low expression of the common leukocyte 
antigen CD45 do, give rise to proliferative endothelial cells even under the same restrictive 
culture conditions, demonstrating the endothelial potential of the CD45−/CD34+ cell 
populations. Recently, a statement from the EULAR Scleroderma Trials and Research 
Group recommended the use of CD34, VEGFR-2 and CD133 antigens to quantify 
circulating EPCs (45). In the present study, we believe, we employed antigenic profiles to 
identify putative EPCs (i.e. CD45−/CD34+ and CD45−/CD34+/VEGFR-2+/CD133+ cells) 
that encompass a cellular phenotype with confirmed endothelial differentiation capacity 
(44;46) and that, importantly, have been linked to cardiovascular disease risk and outcome 
(47–49). Given the lack of consensus in enumerating EPCs, our results must be viewed 
within the context of our antigenic profile. Other enumerating criteria, such as quantifying 
cells double positive for CD34 and VEGFR-2, may yield different results.
In contrast to circulating EPC number, the number of EPC colony-forming units was ~40% 
lower in both obese and overweight compared with normal weight adults. To our 
knowledge, this is the first study to demonstrate an adiposity-related reduction in EPC 
colony-forming capacity. Previous studies that have failed to find a relation between 
adiposity and EPC colony-forming units were either underpowered to detect a difference 
(16), or included a study population that was compromised by statin-use and documented 
CAD (50), factors which have been shown to influence EPC function (12;51). Once thought 
to be a surrogate marker of circulating EPC number, it is now generally accepted that the 
number of EPC colony-forming units does not correspond to the number of circulating EPCs 
measured by flow cytometry (52;53). The discrepancy in our results between EPC number 
(determined by FACS) and the number of colony-forming units further confirm the lack of 
association between these two measures. Nevertheless, clinical interest in EPC colony-
forming units has increased due to the consistently observed relation between colony 
number and both endothelial function (16) and cardiovascular risk in healthy and diseased 
populations (12;21;54). These findings have prompted its use as a novel cardiovascular 
biomarker (11;55). Whether the number of EPC colony-forming units in overweight and 
obese adults is associated with endothelial dysfunction and adverse cardiovascular events 
remains to be determined.
The reasons for the reduced EPC colony-formation in overweight and obese compared with 
normal weight adults are not clear. Recent data indicate that the central clusters of cells that 
make up these colonies are comprised mainly of CD3+/CD31+/CXCR4+ T cells (56;57). 
Thus, it is possible that reduction in this subpopulation of T cells with adiposity is the 
underlying cause. However, in a currently ongoing study focused on these so-called 
“angiogenic T cells,” we have not observed a decline in their number in either overweight or 
obese adults compared with normal weight controls (unpublished observations). It is 
important to emphasize that the defining characteristic of an EPC colony-forming unit is the 
presence of spindle-shaped cells emanating from a central cluster of cells (16). These 
spindle-shaped cells, more so than the central colony clusters, have been shown to 
demonstrate immunologic and morphologic characteristics consistent with the identification 
of putative EPCs (58). It is possible that the same milieu of factors that negatively affect 
circulating EPC number in vivo may also impair their ability to contribute to cluster 
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formation in vitro. Indeed, inflammatory and oxidative substances, such as CRP and 
oxidized LDL-cholesterol, have been shown to impair EPC function in vitro (59;60).
In conclusion, the results of the present study indicate that increased body fatness, 
independent of other traditional cardiovascular risk factors, adversely affects EPC biology. 
Obesity, but not overweight, is associated with lower levels of circulating EPCs compared 
with normal weight adults; whereas, both overweight and obesity are associated with 
blunted EPC colony-forming capacity. While the differential effects of overweight and 
obesity on circulating EPCs require more attention, diminished EPC bioavailability and 
impaired function may contribute to adiposity-related cardiovascular morbidity and 
mortality.
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Figure 1. 
Circulating levels of CD45−/CD34+/VEGFR-2+/CD133+ and CD45−/CD34+ cells in normal 
weight, overweight, and obese adults.
Values are mean ± SE. *P< 0.05 vs. normal weight and overweight.
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Figure 2. 
Endothelial progenitor cell colony forming units for normal weight, overweight, and obese 
adults.
Values are mean ± SE. *P< 0.05 vs. normal weight
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Table 1
Selected subject characteristics
Variable Normal Weight (N=25) Overweight (N=18) Obese (N=24)
Age (years) 56±1 58±1 56±1
Body mass (kg) 70.3±2.1 80.1±2.4* 97.5±2.8*†
BMI (kg/m2) 23.4±0.4 27.6±0.2* 32.9±0.5*†
Body fat (%) 28.8±1.6 31.2±2.1 37.4±1.4*†
Waist circumference (cm) 81.9±2.0 93.0±1.7* 107.8±1.5*†
Systolic BP (mmHg) 118±2 125±2 126±2*
Diastolic BP (mmHg) 72±1 78±1* 81±1*
V̇O2 max (L/min) 2.2±0.1 2.7±0.2 2.6±0.1
V̇O2 max (mL/kg/min) 31.5±1.3 32.4±1.9 27.9±1.4
Maximum heart rate (bpm) 172±3 173±2 171±2
RER at V̇O2 max 1.19±0.01 1.14±0.01 1.16±0.02
Treadmill Time (min) 10.6±0.2 10.5±0.4 9.6±0.3
Total Cholesterol (mmol/L) 5.1±0.1 5.4±0.1 5.3±0.1
HDL-Cholesterol (mmol/L) 1.5±0.1 1.3±0.1 1.2±0.1*
LDL-Cholesterol (mmol/L) 3.1±0.1 3.5±0.1 3.4±0.1
Triglycerides (mmol/L) 1.1±0.1 1.3±0.1 1.4±0.1
Glucose (mmol/L) 4.6±0.1 5.2±0.1 5.1±0.1
Insulin (pmol/L) 32.0±3.5 43.9±3.9 57.0±5.0*
HOMA IR 1.2±0.1 1.7±0.2 2.2±0.2*
BMI, Body Mass Index; BP, blood pressure; V̇O2 max, maximal oxygen consumption; RER, respiratory exchange ratio; LDL, low-density 
lipoprotein; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment-insulin resistance.
Values are mean ± SEM.
*
P<0.05 vs. Normal Weight.
†
P<0.05 vs. Overweight.
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